This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Sarcoma, Myeloid
- Leukemia, Biphenotypic, Acute
- Acute Disease
Age: 18 years - 66+
Gender: All